SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Sun Pharmaceutical Industries gains after its arm gets nod to set up greenfield project

03 Dec 2025 Evaluate

Sun Pharmaceutical Industries is currently trading at Rs 1808.70, up by 10.65 points or 0.59% from its previous closing of Rs 1798.05 on the BSE.

The scrip opened at Rs 1802.95 and has touched a high and low of Rs 1815.95 and Rs 1784.00 respectively. So far 42515 shares were traded on the counter.

The BSE group 'A' stock of face value Rs 1 has touched a 52-week high of Rs 1910.00 on 31-Dec-2024 and a 52-week low of Rs 1547.25 on 26-Sep-2025.

Last one week high and low of the scrip stood at Rs 1843.95 and Rs 1784.00 respectively. The current market cap of the company is Rs 433295.90 crore.

The promoters holding in the company stood at 54.48%, while Institutions and Non-Institutions held 36.78% and 8.73% respectively.

Sun Pharmaceutical Industries’ wholly-owned subsidiary – Sun Pharma Laboratories has received approval from Board of Directors for an investment of Rs 3,000 crore for setting up a greenfield formulations manufacturing facility in Madhya Pradesh.

Earlier, the company had launched its global innovative drug, ILUMYA (Tildrakizumab) in India for moderate-to-severe plaque psoriasis. 

Sun Pharmaceutical Industries is the world's fourth largest specialty generic pharmaceutical company and India's top pharmaceutical company.

Sun Pharma Inds. Share Price

1665.70 -2.30 (-0.14%)
21-Apr-2026 16:01 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1665.70
Dr. Reddys Lab 1220.00
Cipla 1232.60
Zydus Lifesciences 928.05
Lupin 2305.00
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×